Business UpdateApr 21, 2026, 04:06 PM
Foghorn Therapeutics Reports Strong Preclinical Data for Pipeline
AI Summary
Foghorn Therapeutics presented new preclinical data at AACR 2026, highlighting significant progress across its pipeline. The SMARCA2 inhibitor FHD-909 showed complete and durable tumor regression with immune memory when combined with an anti-PD-1 antibody. Additionally, selective CBP and EP300 degraders demonstrated favorable efficacy and safety profiles in various cancer models, with the EP300 degrader outperforming a clinical benchmark. The company also reported robust degradation with its ARID1B degraders, indicating potential for oral bioavailability.
Key Highlights
- FHD-909 showed complete and durable tumor regression with anti-PD-1 in preclinical models.
- FHT-171 (CBP degrader) exhibited strong anti-tumor activity in ER+ breast cancer models.
- Selective EP300 degrader outperformed clinical benchmark in multiple myeloma models.
- ARID1B degraders achieved robust degradation with potential for oral bioavailability.
Price Impact
More from FHTX